2021 American Transplant Congress
Cognition After Belatacept Conversion (CAB) Trial
1Yale University, New Haven, CT, 2Yale New Haven Hospital, New Haven, CT
*Purpose: Extensive adverse effect profiles including neurotoxicity, manifesting as short-term memory loss, make CNIs less desirable despite their efficacy preventing acute rejection and increasing graft…2021 American Transplant Congress
Anti-CD272 Antibody (6B2) Generated Foxp3+Regulatory T Cells and Suppressed Donor Specific Antibody in Murine Cardiac Transplant Model
*Purpose: The co-inhibitory receptor B and T lymphocyte attenuator (BTLA; CD272) has been implicated in the regulation of autoimmune and may potentially play an important…2021 American Transplant Congress
Desensitization Using Costimulatory Blockade and Bortezomib to Prevent DSA Formation and Rejection in Reconstructive Transplantation
*Purpose: Sensitization in form of donor-specific antibodies (DSA) and subsequent antibody-mediated rejection constitute some of the greatest risk factors for allograft rejection and long-term graft…2021 American Transplant Congress
Belatacept Pharmacokinetics in Patients with and without Infection
*Purpose: Two belatacept(BELA) fixed mg/kg dosing regimens, less intense(LI) and more intense(MI) were compared. The LI regimen was approved due to the higher risk profile…2021 American Transplant Congress
Belatacept Pharmacokinetic Analysis Comparing Belatacept Early Steroid Withdrawal Trial (BEST) with Benefit and Benefit-ext Trials
*Purpose: Belatacept(BELA) pharmacokinetic(PK) studies informed dosing in phase 3 studies where fixed mg/kg dosing compared a less intense(LI) and more intense(MI) regimen. LI was preferred…2021 American Transplant Congress
Belatacept Conversion in Elderly Renal Transplant Recipients
1UW Health, Madison, WI, 2University of Wisconsin School of Medicine and Public Health, Madison, WI
*Purpose: Describe the impact of conversion from a calcineurin inhibitor (CNI) based immunosuppressive regimen to belatacept in elderly renal transplant recipients.*Methods: Adult renal transplant patients…2021 American Transplant Congress
Infectious Complications After Belatacept Conversion in Kidney Transplant
*Purpose: Tacrolimus (tac), a calcineurin inhibitor, is associated with multiple adverse effects when used for immunosuppression following kidney transplant (KT). Belatacept (bela) is a monoclonal…2021 American Transplant Congress
A Comparison of Belatacept Conversion Regimens from Calcineurin Inhibitor-Based Immunosuppression
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: Outcomes with varying belatacept conversion protocols from calcineurin inhibitor (CNI)-based immunosuppression have been published but no standard protocol has been established. Beginning in 2012,…2021 American Transplant Congress
Renal Preservation with Belatacept-Based versus Everolimus-Based Immunosuppression in Lung Transplant Recipients
*Purpose: Renal dysfunction is one of the most common long-term complications among lung transplant recipients (LTRs). Calcineurin-inhibitor (CNI) nephrotoxicity is a recognized contributor to renal…2021 American Transplant Congress
Tolerability of De Novo and Conversion Belatacept Regimens in Kidney Transplantation
*Purpose: Belatacept, a selective T lymphocyte co-stimulation blocker, has been shown to be a safe and effective maintenance therapy for immunosuppression. We investigated the long-term…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 30
- Next Page »